“The way we learn what works and to make recommendations to our patients is based on #clinicaltrials. It’s really a crisis. And it’s a societal imperative, in my opinion, to fix this problem of clinical trial representativeness.” Building off an article published in NEJM Evidence, data-driven approaches have the ability to transform #oncology trials, improve patient outcomes, and address disparities in health care. Read more in a recent interview with Neal Meropol, Head of Clinical Oncology at Flatiron Health, and The Evidence Base®. http://spkl.io/604247EtE
Flatiron Health’s Post
More Relevant Posts
-
In this interview, Dr. Meropol speaks to access to oncology clinical trials, representation in clinical trials, and technology in clinical trials. Timely topics for the healthcare industry. I encourage you to give this a read!
“The way we learn what works and to make recommendations to our patients is based on #clinicaltrials. It’s really a crisis. And it’s a societal imperative, in my opinion, to fix this problem of clinical trial representativeness.” Building off an article published in NEJM Evidence, data-driven approaches have the ability to transform #oncology trials, improve patient outcomes, and address disparities in health care. Read more in a recent interview with Neal Meropol, Head of Clinical Oncology at Flatiron Health, and The Evidence Base®. http://spkl.io/604247EtE
The role of data-driven insights in shaping inclusive cancer clinical trials: an interview with Neal Meropol, Flatiron Health
evidencebaseonline.com
-
Clinical trials need to be representative if we expect the results to be applicable to ALL cancer patients. Let's double down to help address this imperative by carefully designing trials that optimize patient access. Let's all commit to taking a data-driven approach to defining eligibility criteria, and reducing site burden by focusing data collection on only those elements absolutely critical to study objectives!
“The way we learn what works and to make recommendations to our patients is based on #clinicaltrials. It’s really a crisis. And it’s a societal imperative, in my opinion, to fix this problem of clinical trial representativeness.” Building off an article published in NEJM Evidence, data-driven approaches have the ability to transform #oncology trials, improve patient outcomes, and address disparities in health care. Read more in a recent interview with Neal Meropol, Head of Clinical Oncology at Flatiron Health, and The Evidence Base®. http://spkl.io/604247EtE
The role of data-driven insights in shaping inclusive cancer clinical trials: an interview with Neal Meropol, Flatiron Health
evidencebaseonline.com
-
Associate Principal @ Flatiron Health | Former Caris Life Sciences & Pharmatech | Driving Oncology Clinical Research & Evidence Innovation
Great podcast listen here about the importance of representation in oncology clinical trials, the role of technology in clinical trials, creating more access to clinical trials, and improving clinical trial design.
“The way we learn what works and to make recommendations to our patients is based on #clinicaltrials. It’s really a crisis. And it’s a societal imperative, in my opinion, to fix this problem of clinical trial representativeness.” Building off an article published in NEJM Evidence, data-driven approaches have the ability to transform #oncology trials, improve patient outcomes, and address disparities in health care. Read more in a recent interview with Neal Meropol, Head of Clinical Oncology at Flatiron Health, and The Evidence Base®. http://spkl.io/604247EtE
The role of data-driven insights in shaping inclusive cancer clinical trials: an interview with Neal Meropol, Flatiron Health
evidencebaseonline.com
-
The traditional model of #clinicaltrials, while essential, often faces challenges in representing diverse patient populations and real-world scenarios. Recent advancements highlighted in an article published in NEJM Evidence emphasize the potential of #RWD to bridge these gaps. In this interview with Neal Meropol, Vice President of Research Oncology at Flatiron Health, we explore how these data-driven approaches are transforming #oncology trials, improving #patientoutcomes, and addressing disparities in health care. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #realworldevidence #realworlddata #regulation #regulatoryaffairs #healthdata #healthequity #healthpolicy
The role of data-driven insights in shaping inclusive cancer clinical trials: an interview with Neal Meropol, Flatiron Health
evidencebaseonline.com
-
Raising awareness of this excellent Australian Symposium on Precision Oncology. Registrations open. #APOS2024 #APOS24 #CancerMeetsItsMatch #CancerResearch #Omico #CancerTreatment #ZoomWebinar #CancerCare #GroundbreakingResearch #InnovativeMedicine #HealthcareTech #VirtualLearning #FightCancer #ResearchforCure #Research #CancerAwareness #BeatCancer #MedicalInnovations #CancerSolutions #MedicalBreakthroughs #OncologyResearch #ScienceAndHealth #CancerInsights #LifeScience
Have you registered for the Australian Precision Oncology Symposium 2024 (#APOS24) yet? The #Symposium will feature a blend of plenary style lectures and panel discussions that delve into precision oncology topics. These sessions will explore the latest evidence and its implications for health, health systems, and integration into models of care. Additionally, key areas of focus will include the role of real-world data, funding models, as well as discussions on heritability and early detection of cancer in high-risk populations. You will have the chance to #connect with experts in the field, share insights, and build valuable professional relationships. Want to know more? Click here for in person attendance: https://lnkd.in/gAtFgK7r Click here for online attendance: https://lnkd.in/gb3GjQts #APOS2024 #APOS24 #CancerMeetsItsMatch #CancerResearch #Omico #CancerTreatment #ZoomWebinar #CancerCare #GroundbreakingResearch #InnovativeMedicine #HealthcareTech #VirtualLearning #FightCancer #MedicalOncologist #ResearchforCure #Research #CancerAwareness #BeatCancer #MedicalInnovations #CancerSolutions #MedicalBreakthroughs #OncologyResearch #ScienceAndHealth #CancerInsights #LifeScience
-
-
#Diversity matters in healthcare. Research from one of our studies showed that the number of White physicians was proportionate to the number of White patients, while the number of Black and Asian physicians was not proportionate to the population in Virginia. To bolster communication and trust between physicians and patients—especially in cases where the race/ethnicity of patients and providers are not the same—experience and training in cultural competencies is critical. Further, it may also lead to better patient outcomes. As evidenced by our study, patients with physicians with a racially/ethnically diverse patient panel had higher odds of colorectal cancer screening. Read more ➡️ https://bit.ly/3TE62Hm
-
-
Executive Medical Director | Editor-in-Chief, AI in Precision Oncology | Founder, Tensor Black | American Cancer Society Board OH/KY | ACCC Exec Board | AI Consultant | Board Advisor | Keynote Speaker
Kudos to AI in Precision Oncology editor Blythe Adamson, PhD, MPH, for her thoughtful and careful application of real-world evidence (RWE) to complement clinical trials. RWE plays a crucial role in addressing questions that traditional trials may not fully answer, particularly when utilizing large and diverse datasets. Blythe’s work underscores the importance of RWE in enhancing our understanding of treatment outcomes and patient care. Keep pushing forward, Blythe—excited to see the innovative solutions you bring to cancer research (and your manuscripts :)) Flatiron Health James Hamrick #CancerResearch #RealWorldEvidence #ClinicalTrials #OncologyInnovation
The demand for #RWD on patients with cancer in Europe and Japan is increasing, particularly as many regulatory and #HTA bodies have stated a clear preference for local data in guidance on #RWE. At Flatiron Health, we're addressing this gap by now having EHR-derived data from the UK, Germany, and Japan. Hear Blythe Adamson, PhD, MPH, Head of Outcomes Research & Evidence Generation, share how Flatiron is filling critical evidence generation gaps with global oncology #realworlddata.
-
Vice President and Global Head of Centralized Delivery : Championing Innovation and Strategic Organizational Leadership
Exploring 'Overcoming Barriers in Cancer Clinical Trials,' it's clear the urgent need for reform in how clinical trials are integrated into cancer care. With enrollment challenges and systemic issues at play, what steps can we take to improve patient access and trial effectiveness?
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient Care
share.postbeyond.com
-
The demand for #RWD on patients with cancer in Europe and Japan is increasing, particularly as many regulatory and #HTA bodies have stated a clear preference for local data in guidance on #RWE. At Flatiron Health, we're addressing this gap by now having EHR-derived data from the UK, Germany, and Japan. Hear Blythe Adamson, PhD, MPH, Head of Outcomes Research & Evidence Generation, share how Flatiron is filling critical evidence generation gaps with global oncology #realworlddata.
-
As digital health continues to shape the landscape of oncology, our solution stands out as a vital asset for oncology service line leaders, health system executives, and individual care providers. With Genomate, you can streamline treatment decisions, enhance patient outcomes, and alleviate financial burdens. Why choose Genomate? 📍 Tailor treatment recommendations based on comprehensive genomic analysis 📍 Optimize treatment plans to maximize efficacy and minimize side effects 📍 Empower all patients with equitable access to state-of-the-art cancer care Learn more: https://lnkd.in/e-iGq8hs #GenomateHealth #PrecisionOncology
-
